NYSEARCA:CATX • US46489V3024
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PERSPECTIVE THERAPEUTICS INC (CATX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-18 | UBS | Maintains | Buy -> Buy |
| 2026-03-18 | B. Riley Securities | Maintains | Buy -> Buy |
| 2026-03-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-03-17 | BTIG | Reiterate | Buy -> Buy |
| 2026-03-17 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-19 | Piper Sandler | Initiate | Overweight |
| 2026-01-30 | Wedbush | Reiterate | Outperform -> Outperform |
| 2026-01-30 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-13 | BTIG | Reiterate | Buy -> Buy |
| 2025-11-21 | UBS | Maintains | Buy -> Buy |
| 2025-11-18 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-10-13 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-10 | BTIG | Initiate | Buy |
| 2025-10-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-06-23 | B. Riley Securities | Maintains | Buy -> Buy |
| 2025-06-23 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-06-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-07 | Truist Securities | Maintains | Buy -> Buy |
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-27 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-27 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-13 | HC Wainwright & Co. | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 10.8M 7.46% | 1.434M -86.72% | 1.454M 1.39% | 1.085M -25.38% | 996.336K -8.17% | 765.133K -23.21% | 25.484M 3,230.66% | 221.43M 768.90% | 258.03M 16.53% | 464.94M 80.19% | 674.12M 44.99% | 839.01M 24.46% | |
| EBITDA YoY % growth | -7.1M -118.46% | -39.955M -462.75% | -64.491M -61.41% | -103.851M -61.03% | -117.203M -12.86% | -97.706M 16.64% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -7.39M -114.83% | -40.941M -454.01% | -66.797M -63.15% | -104.349M -56.22% | -128.872M -23.50% | -140.962M -9.38% | -156.27M -10.86% | -20.265M 87.03% | 21.998M 208.55% | 183.84M 735.71% | 352.23M 91.60% | 478.62M 35.88% | |
| Operating Margin | -68.43% | -2,855.02% | -4,594.02% | -9,617.40% | -12,934.60% | -18,423.27% | -613.21% | -9.15% | 8.53% | 39.54% | 52.25% | 57.05% | |
| EPS YoY % growth | -0.05 -25.00% | N/A -2,619.93% | -0.84 38.23% | -1.27 -51.20% | -1.28 -0.84% | -1.13 11.59% | -1.16 -2.03% | -1.09 5.81% | -0.54 50.62% | 0.34 162.65% | 1.30 284.85% | 1.94 49.61% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.36 -45.44% | -0.34 -36.21% | -0.37 -26.21% | -0.39 -12.20% | -0.39 -8.38% |
| Revenue Q2Q % growth | 219.932K -6.01% | 149.94K -56.16% | 153K -47.24% | 132.6K -36.56% | 132.6K -39.71% |
| EBITDA Q2Q % growth | -30.503M -64.09% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -29.954M -43.35% | -25.983M -19.01% | -31.14M -29.54% | -32.848M -17.90% | -32.438M -8.29% |
All data in USD
20 analysts have analysed CATX and the average price target is 12.95 USD. This implies a price increase of 181.44% is expected in the next year compared to the current price of 4.6.
PERSPECTIVE THERAPEUTICS INC (CATX) will report earnings on 2026-04-27.
The consensus EPS estimate for the next earnings of PERSPECTIVE THERAPEUTICS INC (CATX) is -0.36 USD and the consensus revenue estimate is 219.93K USD.
The number of analysts covering PERSPECTIVE THERAPEUTICS INC (CATX) is 20.